Ailux Teams with Lilly to Accelerate AI Antibody Development

AI-TechParkWednesday, November 5, 2025 at 2:30:00 PM
Ailux, a subsidiary of XtalPi, has partnered with Eli Lilly to enhance the development of bispecific antibodies using AI technology. This collaboration is significant as it aims to expedite the discovery process for treatments targeting various diseases, potentially leading to faster and more effective therapies for patients.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Researchers used AI to design functional antibodies from scratch, suggesting that AI tools could speed up antibody discovery without the need for animal testing (Financial Times)
PositiveArtificial Intelligence
Researchers have successfully utilized AI to create functional antibodies from scratch, marking a significant advancement in antibody discovery. This breakthrough not only highlights the potential of AI tools in accelerating research but also suggests a future where animal testing may no longer be necessary. This is important as it could lead to faster development of treatments and vaccines, ultimately benefiting public health.
POEMS: Product of Experts for Interpretable Multi-omic Integration using Sparse Decoding
PositiveArtificial Intelligence
The introduction of POEMS, or Product Of Experts for Interpretable Multiomics Integration, marks a significant advancement in the field of disease research. This innovative approach addresses the challenge of integrating various molecular layers without sacrificing interpretability or predictive performance. By overcoming the limitations of traditional deep generative models, POEMS enhances our ability to understand complex diseases, which could lead to better diagnostics and treatments. This development is crucial as it paves the way for more effective healthcare solutions.